第一单位：
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jcortes@mdanderson.org.
作者：
Jorge,Cortes [1]
;
Alexander E,Perl [2]
;
Hartmut,Döhner [3]
;
Hagop,Kantarjian [4]
;
Giovanni,Martinelli [5]
;
Tibor,Kovacsovics [6]
;
Philippe,Rousselot [7]
;
Björn,Steffen [8]
;
Hervé,Dombret [9]
;
Elihu,Estey [10]
;
Stephen,Strickland [11]
;
Jessica K,Altman [12]
;
Claudia D,Baldus [13]
;
Alan,Burnett [14]
;
Alwin,Krämer [15]
;
Nigel,Russell [16]
;
Neil P,Shah [17]
;
Catherine C,Smith [17]
;
Eunice S,Wang [18]
;
Norbert,Ifrah [19]
;
Guy,Gammon [20]
;
Denise,Trone [20]
;
Deborah,Lazzaretto [20]
;
Mark,Levis [21]
作者单位：
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jcortes@mdanderson.org.
[1]
Division of Hematology and Oncology, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
[2]
Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
[3]
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
[4]
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, Italy.
[5]
Center for Hematologic Malignancies, Oregon Health & Science University, Portland, OR, USA.
[6]
Service d'Hématologie et Oncologie, Hôpital de Versailles, Université Versailles Saint-Quentin-en-Yvelines Paris-Saclay U1173, Le Chesnay, France.
[7]
Department of Medicine II, Hematology/Oncology, Goethe University, Frankfurt, Germany.
[8]
University Hospital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot, Paris, France.
[9]
Seattle Cancer Care Alliance, University of Washington School of Medicine, Seattle, WA, USA.
[10]
Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
[11]
Department of Medicine, Division of Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
[12]
Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hematology and Oncology, Berlin, Germany.
[13]
Department of Haematology, Cardiff University, Cardiff, Wales, UK.
[14]
Klinische Kooperationseinheit Molekulare Hämatologie/Onkologie, Medizinische Klinik V, Universität Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
[15]
Department of Haematology, Nottingham University Hospital, Nottingham, UK.
[16]
Department of Medicine, Division of Hematology and Oncology, University of California at San Francisco, San Francisco, CA, USA.
[17]
Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
[18]
Service des Maladies du Sang, Centre Hospitalier Universitaire d'Angers, Angers, France.
[19]
Daiichi Sankyo, San Diego, CA, USA.
[20]
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
[21]
主题词
投药, 口服(Administration, Oral);成年人(Adult);老年人(Aged);苯并噻唑类(Benzothiazoles);加拿大(Canada);无病生存(Disease-Free Survival);剂量效应关系, 药物(Dose-Response Relationship, Drug);用药计划表(Drug Administration Schedule);欧洲(Europe);女(雌)性(Female);人类(Humans);国际性(Internationality);白血病, 髓样, 急性(Leukemia, Myeloid, Acute);男(雄)性(Male);最大耐受剂量(Maximum Tolerated Dose);中年人(Middle Aged);肿瘤复发, 局部(Neoplasm Recurrence, Local);苯脲化合物(Phenylurea Compounds);预后(Prognosis);存活率(Survival Rate);治疗结果(Treatment Outcome);美国(United States);青年人(Young Adult);fms样酪氨酸激酶3(fms-Like Tyrosine Kinase 3)
DOI
10.1016/S1470-2045(18)30240-7
PMID
29859851
发布时间
2023-01-20
换一批
换一批
